In 1928, Alexander Fleming discovered penicillin. However, it took another 12 years to start extracting it and the crises of the Second World War to catapult its production into a reality. Today, our fight is against fast developing antimicrobial resistance – we cannot afford to wait 12 years to develop a solution.

Matoke® Pharma is the pharmaceutical division of Matoke® Holdings Ltd, developing new treatments based on Reactive Oxygen® technology, which represents a major technological advance in infection management. Following in the footsteps of Fleming, our mission is to utilise Reactive Oxygen® to create novel antimicrobial medical products which can penetrate biofilms and are much more than conventional antibiotics. Reactive Oxygen® has a low propensity for developing resistance and bacteria have to date not been observed to have developed resistance to it – making it a potentially crucial tool in helping address the ever-increasing global threat of antimicrobial resistance (AMR).

Matoke® Holdings Ltd is a privately-owned UK-based pharmaceutical company, a member of the BioIndustry Association (BIA) and registered Small or Medium-sized Enterprise (SME) with the European Medicines Agency (EMA).

We cannot afford to wait decades to transform the way we tackle drug-resistant infections. Reactive Oxygen® technology opens a new front in the fight against antibiotic resistance

Ian Staples

Founder and CEO of Matoke Holdings Ltd.™

Please find further information about our team below: